

Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria

Leuven, Belgium, 17 September 2018 – Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that it will give two presentations at the Euretina International Congress, which is being held in Vienna, Austria, from 20 to 23 September 2018.

The presentation “*Anti-inflammatory effects of the PIGF neutralizing antibody THR-317 in patients with diabetic macular edema*” will be given by Oxurion senior scientist Dr. Michaël Porcu. The presentation will take place at 6pm CET, Friday 21 September at the Free Paper Session 11 on New Drug Treatment & Technology I (Room C1).

THR-317 is a PIGF neutralizing monoclonal antibody being developed for the treatment of Diabetic Macular Edema (DME). THR-317 is in a Phase 2 study evaluating the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab (Lucentis®).

The presentation “*Therapeutic effect of the potent integrin antagonist THR-687 in the cynomolgus laser-induced choroidal neovascularization model confirms its potential as novel treatment for sight-threatening retinal pathologies*” will be given by Oxurion scientist Dr. Tjing-Tjing Hu. The presentation will take place on Saturday 22 September at 3.06pm CET at the Free Paper Session 18 on New Drug Treatment & Technology II (Room C4).

THR-687 is a small molecule pan-RGD integrin antagonist being developed to treat a broad range of patients with diabetic eye disease. THR-687 is expected to enter the clinic shortly.

“*We are pleased to have the opportunity to present our cutting-edge research in the field of diabetic eye disease at Euretina*”, said Dr. Patrik De Haes, CEO of Oxurion nv. “*There is a clear unmet medical need for improved treatment options for diabetic eye disease. Oxurion is focused on addressing this need and is developing multiple new therapies, including THR-317 and THR-687, each with the potential to improve on the current standard of care for a number of diabetic eye disease indications.*”

Visit Oxurion booth #C228 for meeting up with the Oxurion team.

-Ends-

For further information please contact:

Oxurion NV Wouter Piepers , Global Head of Corp Coms & Investor relations Tel: +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com	
Citigate Dewe Rogerson David Dible / Sylvie Berrebi Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com	US - LifeSci Public Relations Alison Chen Tel: +1 646-876-4932 achen@lifescipublicrelations.com

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.

Oxurion's clinical pipeline consists of THR-317, a PIGF inhibitor, for the treatment of diabetic macular edema (DME); THR-149, a plasma kallikrein inhibitor for the treatment of DME; and THR-687, a pan-RGD integrin antagonist for the treatment of diabetic retinopathy and DME. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.

Oxurion owns the global rights to JETREA[®] (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company. More information is available at www.oxurion.com

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.